רדאר קליני AI | ||
|---|---|---|
הניסוי הקליני NCT03758443 (RHEA) עבור קוליטיס כיבית (UC) הוא הופסק. לכל הפרטים, עיינו בתצוגת הכרטיסים של רדאר ניסויים קליניים ובכלי הגילוי של AI. אפשר גם לשאול כל דבר כאן. | ||
מחקר אחד תואם לקריטריוני המסנן
תצוגת כרטיסים
חזרה לחיפוש
תרבנס ביופארמהEfficacy & Safety of TD-1473 in Ulcerative Colitis (RHEA) שלב II, שלב III 239
פרטי הניסויים הקליניים זמינים בעיקר באנגלית. רדאר קליני AI יכול לעזור! לחץ על 'הסבר את המחקר' כדי לצפות ולשוחח על מידע מהמחקר בשפה המועדפת עליך.
ניסוי קליני NCT03758443 (RHEA) מתקיים כדי לבדוק את טיפול עבור קוליטיס כיבית (UC). זהו מחקר שלב II שלב III מסוג התערבותי שנמצא כעת במצב הופסק. המחקר התחיל ב-11 במרץ 2019 ומתוכנן לכלול 239 משתתפים. המחקר מנוהל על ידי תרבנס ביופארמה וצפוי להסתיים ב-20 באוקטובר 2021. מידע זה עודכן לאחרונה באתר ClinicalTrials.gov ב-15 בנובמבר 2022.
סיכום קצר
A Phase 2b/3 set of studies to evaluate the efficacy and safety of induction and maintenance therapy with TD-1473 in subjects with moderately-to-severely active ulcerative colitis with up to 60 weeks of treatment.
תיאור מפורט
This protocol consists of 3 separate studies: an 8-week Phase 2b dose-finding induction study, an 8-week dose-confirming Phase 3 induction study, and a 44-week Phase 3 maintenance study. Subjects who respond to induction will enter the maintenance study; those who do not will receive TD-1473 during extended induction. The safety and efficacy data of the Phase 2b study will be analyzed to select the induction and main...הצג עוד
כותרת רשמית
A Phase 2b/3 Multi-Center, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled, Parallel-Group Set of Studies to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With TD-1473 in Subjects With Moderately-to-Severely Active Ulcerative Colitis
מצבים רפואיים
קוליטיס כיבית (UC)מזהי מחקר נוספים
- RHEA
- 0157
- 2018-002136-24 (מספר EudraCT)
מספר NCT
תחילת המחקר (בפועל)
2019-03-11
עדכון אחרון שפורסם
2022-11-15
סיום המחקר (מוערך)
2021-10-20
משתתפים (מתוכנן)
239
סוג המחקר
התערבותי
שלב
שלב II
שלב III
שלב III
סטטוס
הופסק
מילות מפתח
TD-1473
Janus kinase inhibitor
JAK inhibitor
Inflammatory Bowel Disease
IBD
Ulcerative colitis
UC
Gut selective
Janus kinase inhibitor
JAK inhibitor
Inflammatory Bowel Disease
IBD
Ulcerative colitis
UC
Gut selective
מטרה ראשית
טיפול
הקצאת טיפול
אקראי
דגם מתערב
קבוצות מקבילות
עיוורון
מרובע
זרועות / התערבויות
| קבוצת משתתפים/זרוע | התערבות/טיפול |
|---|---|
ניסיActive Treatment TD-1473 Dose A Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction. | TD-1473 Dose A See Arm description |
ניסיActive Treatment TD-1473 Dose B Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction. | TD-1473 Dose B See Arm description |
ניסיActive Treatment TD-1473 Dose C Participants will be randomized to receive an oral daily dose of TD-1473. Responders will be re-randomized into the Phase 3 Maintenance portion of the study. Non-responders may participate in an extended induction. | TD-1473 Dose C See Arm description |
פלצבו להשוואהPlacebo Participants will be randomized to receive an oral daily dose of placebo. Participants who received Placebo (and were non-responders) may move to an extended induction. Subjects who are on placebo will be assigned to active TD-1473 for the extended induction (they will be blinded to dose). | פלצבו See Arm description |
מדדי תוצאה ראשיים
מדדי תוצאה משניים
| מדד תוצאה | תיאור המדידה | טווח זמן |
|---|---|---|
Change From Baseline in Total Mayo Score (tMS) at Week 8 | Total Mayo Score (tMS) was calculated as the sum of four components: rectal bleeding (0-3), stool frequency (0-3), physician's global assessment (0-3) and Mayo endoscopic subscore (0-3). tMS was reported as a 0-12 point score with 12 reflecting the highest severity. | Baseline to Week 8 |
Phase 3 Maintenance: Number of Participants Who Demonstrated Clinical Remission by Adapted Mayo Score Components at Maintenance Week (mWeek) 44 | Clinical remission by Adapted Mayo score was defined based on Adapted Mayo score components within specific ranges: stool frequency score of 0 or 1, a rectal bleeding subscore of 0 and a Mayo endoscopy subscore of 0 or 1.
The Adapted Mayo score was the sum of three components: rectal bleeding, stool frequency, and Mayo endoscopic subscore, each measured on a scale of 0-3 with higher scores reflecting higher severity.
Participants with missing Week 44 values were imputed as non-responders. | mWeek 44 |
| מדד תוצאה | תיאור המדידה | טווח זמן |
|---|---|---|
Number of Participants Who Demonstrated Clinical Remission by Adapted Mayo Score Components at Week 8 | Clinical remission by Adapted Mayo score was defined based on Adapted Mayo score components within specific ranges: stool frequency score of 0 or 1, a rectal bleeding subscore of 0 and a Mayo endoscopy subscore of 0 or 1.
The Adapted Mayo score was the sum of three components: rectal bleeding, stool frequency, and Mayo endoscopic subscore, each measured on a scale of 0-3 with higher scores reflecting higher severity. | Week 8 |
Phase 3 Maintenance: Number of Participants Who Demonstrated a Clinical Response by Adapted Mayo Score Components at mWeek 44 | Clinical response was defined as a reduction from baseline in adapted Mayo score of ≥ 2 points and ≥ 30% relative to baseline. It also required ≥ 1 reduction in the rectal bleeding subscore or an absolute subscore ≤ 1.
The Adapted Mayo score was the sum of three components: rectal bleeding, stool frequency, and Mayo endoscopic subscore, each measured on a scale of 0-3 with higher scores reflecting higher severity.
Participants with missing Week 44 values were imputed as non-responders. | Baseline to mWeek 44 |
Phase 3 Maintenance: Number of Participants Who Demonstrated Endoscopic Remission by Adapted Mayo Score Components at mWeek 44 | Endoscopic remission was defined as an endoscopic subscore ≤ 1.
Endoscopic subscore was measured using scale of 0-3, where higher numbers reflected greater severity. | mWeek 44 |
Phase 3 Maintenance: Number of Participants Who Demonstrated Symptomatic Remission by Adapted Mayo Score Components at mWeek 44 | Symptomatic remission was defined as a stool frequency score ≤ 1 and a rectal bleeding subscore of 0.
Stool frequency score and rectal bleeding score were each measured using scale of 0-3, where higher numbers reflected greater severity.
Participants with missing Week 44 values were imputed as non-responders. | mWeek 44 |
קריטריוני זכאות
גילאים מוערכים למחקר
מבוגר, גיל שלישי
גיל מינימלי למחקר
18 Years
מגדרים מוערכים למחקר
הכל
- Is at least 18 years of age at screening
- Has a history of UC for at least 3 months prior to screening
- Has moderately-to-severely active UC, as defined by a Mayo endoscopic subscore of ≥2 points and an adapted Mayo score between 4 - 9 points inclusive
- Is corticosteroid-dependent or has demonstrated inadequate response, or intolerance to conventional therapy (aminosalicylates, corticosteroids, immunomodulators) or biologics
- Willing to use highly-effective methods of contraception during the study and for 7 days after the last dose
- Additional inclusion criteria apply
- Has symptoms suggestive of fulminant colitis, megacolon or intestinal perforation
- Likely to require surgery for UC or other major surgeries
- Has previously received / is currently receiving prohibited medications within specified timeframe
- Is refractory to 3 biologics with ≥2 mechanisms of action
- Has a current bacterial, parasitic, fungal, or viral infection
- Has clinically significant abnormalities in laboratory evaluations
- Has had any prior exposure to an approved Janus kinase (JAK) inhibitor or potential exposure to an investigational JAK inhibitor that was stopped due to intolerance or lack of efficacy
- Additional exclusion criteria apply
תרבנס ביופארמהאין נתוני קשר.
188 מיקומי המחקר ב-22 מדינות
Rehoboth
Theravance Biopharma Investigational Site, Ẕerifin, Rehoboth, 7030000, Israel
Theravance Biopharma Investigational Site, Haifa, 31048, Israel
Theravance Biopharma Investigational Site, Holon, 5822012, Israel
Theravance Biopharma Investigational Site, Jerusalem, 9362410, Israel
Theravance Biopharma Investigational Site, Nahariya, 2210001, Israel
Theravance Biopharma Investigational Site, Petah Tikva, 4941492, Israel
Theravance Biopharma Investigational Site, Rehovot, 7661041, Israel
California
Theravance Biopharma Investigational Site, Chula Vista, California, 91911, United States
Theravance Biopharma Investigational Site, La Jolla, California, 92037, United States
Theravance Biopharma Investigational Site, Lancaster, California, 93534, United States
Theravance Biopharma Investigational Site, Orange, California, 92866, United States
Colorado
Theravance Biopharma Investigational Site, Colorado Springs, Colorado, 80920, United States
Florida
Theravance Biopharma Investigational Site, Aventura, Florida, 33180, United States
Theravance Biopharma Investigational Site, Clearwater, Florida, 33756, United States
Theravance Biopharma Investigational Site, Largo, Florida, 33777, United States
Theravance Biopharma Investigational Site, Miami, Florida, 33135, United States
Theravance Biopharma Investigational Site, Miami, Florida, 33155, United States
Theravance Biopharma Investigational Site, New Port Richey, Florida, 34653, United States
Theravance Biopharma Investigational Site, New Smyrna Beach, Florida, 32168, United States
Theravance Biopharma Investigational Site, Orlando, Florida, 32803, United States
Theravance Biopharma Investigational Site, Pembroke Pines, Florida, 33024, United States
Georgia
Theravance Biopharma Investigational Site, Atlanta, Georgia, 30342, United States
Theravance Biopharma Investigational Site, Suwanee, Georgia, 30024, United States
Idaho
Theravance Biopharma Investigational Site, Idaho Falls, Idaho, 83404, United States
Kansas
Theravance Biopharma Investigational Site, Kansas City, Kansas, 66160, United States
Kentucky
Theravance Biopharma Investigational Site, Louisville, Kentucky, 40202, United States
Louisiana
Theravance Biopharma Investigational Site, Monroe, Louisiana, 71201, United States
Maryland
Theravance Biopharma Investigational Site, Baltimore, Maryland, 21201, United States
Michigan
Theravance Biopharma Investigational Site, Troy, Michigan, 48098, United States
Theravance Biopharma Investigational Site, Wyoming, Michigan, 48519, United States
Minnesota
Theravance Biopharma Investigational Site, Rochester, Minnesota, 55905, United States
Missouri
Theravance Biopharma Investigational Site, Kansas City, Missouri, 64131, United States
Nevada
Theravance Biopharma Investigational Site, Las Vegas, Nevada, 89123, United States
New York
Theravance Biopharma Investigational Site, New York, New York, 10029, United States
North Carolina
Theravance Biopharma Investigational Site, Charlotte, North Carolina, 28215, United States
Theravance Biopharma Investigational Site, Gastonia, North Carolina, 28054, United States
Theravance Biopharma Investigational Site, Greenville, North Carolina, 27834-3761, United States
Pennsylvania
Theravance Biopharma Investigational Site, Pittsburgh, Pennsylvania, 15212, United States
Theravance Biopharma Investigational Site, Smithfield, Pennsylvania, 15478, United States
South Carolina
Theravance Biopharma Investigational Site, Greenville, South Carolina, 29615, United States
Theravance Biopharma Investigational Site, Rock Hill, South Carolina, 29732, United States
Tennessee
Theravance Biopharma Investigational Site, Nashville, Tennessee, 37212, United States
Texas
Theravance Biopharma Investigational Site, Garland, Texas, 75044, United States
Theravance Biopharma Investigational Site, Houston, Texas, 77002, United States
Theravance Biopharma Investigational Site, San Antonio, Texas, 78215, United States
Queensland
Theravance Biopharma Investigational Site, South Brisbane, Queensland, 4101, Australia
Theravance Biopharma Investigational Site, Woolloongabba, Queensland, 4102, Australia
Victoria
Theravance Biopharma Investigational Site, Malvern, Victoria, 3144, Australia
Western Australia
Theravance Biopharma Investigational Site, Murdoch, Western Australia, 6150, Australia
Sofia
Theravance Biopharma Investigational Site, Sofia, Sofia, 1303, Bulgaria
Theravance Biopharma Investigational Site, Sofia, Sofia, 1527, Bulgaria
Theravance Biopharma Investigational Site, Sofia, Sofia, 1784, Bulgaria
Theravance Biopharma Investigational Site (2), Pleven, 5800, Bulgaria
Theravance Biopharma Investigational Site, Pleven, 5800, Bulgaria
Theravance Biopharma Investigational Site, Plovdiv, 4002, Bulgaria
Theravance Biopharma Investigational Site, Plovdiv, 4004, Bulgaria
Theravance Biopharma Investigational Site, Rousse, 7005, Bulgaria
Theravance Biopharma Investigational Site, Sliven, 8800, Bulgaria
Theravance Biopharma Investigational Site, Sofia, 1712, Bulgaria
Theravance Biopharma Investigational Site, Stara Zagora, 6000, Bulgaria
Theravance Biopharma Investigational Site, Stara Zagora, 6001, Bulgaria
Theravance Biopharma Investigational Site, Veliko Tarnovo, 5000, Bulgaria
Ontario
Theravance Biopharma Investigational Site, Kingston, Ontario, K7L 5G2, Canada
Auvergne-Rhône-Alpes
Theravance Biopharma Investigational Site, Pierre-Bénite, Auvergne-Rhône-Alpes, 69495, France
Theravance Biopharma Investigational Site, Saint-Etienne, Auvergne-Rhône-Alpes, 42055, France
Champagne-ardenne
Theravance Biopharma Investigational Site, Reims, Champagne-ardenne, 51092, France
Hauts-de-France
Theravance Biopharma Investigational Site, Lille, Hauts-de-France, 59037, France
Languedoc-roussillon
Theravance Biopharma Investigational Site, Montpellier, Languedoc-roussillon, 34295, France
Limousin
Theravance Biopharma Investigational Site, Vandœuvre-lès-Nancy, Limousin, 54500, France
Midi-pyrenees
Theravance Biopharma Investigational Site, Toulouse, Midi-pyrenees, 31059, France
Pays de la Loire Region
Theravance Biopharma Investigational Site, Nantes, Pays de la Loire Region, 44000, France
Picardie
Theravance Biopharma Investigational Site, Amiens, Picardie, 80054, France
Theravance Biopharma Investigational Site, Batumi, 6010, Georgia
Theravance Biopharma Investigational Site, Tbilisi, 0114, Georgia
Theravance Biopharma Investigational Site, Tbilisi, 0159, Georgia
Baden-Wurttemberg
Theravance Biopharma Investigational Site, Heidelberg, Baden-Wurttemberg, 69121, Germany
Theravance Biopharma Investigational Site, Ulm, Baden-Wurttemberg, 89081, Germany
Schleswig-Holstein
Theravance Biopharma Investigational Site, Kiel, Schleswig-Holstein, 24105, Germany
Thuringia
Theravance Biopharma Investigational Site, Jena, Thuringia, 07747, Germany
Theravance Biopharma Investigational Site, Berlin, 10117, Germany
Theravance Biopharma Investigational Site, Berlin, 13353, Germany
Attica
Theravance Biopharma Investigational Site, Athens, Attica, 115 27, Greece
Theravance Biopharma Investigational Site #2, Athens, Attica, 11527, Greece
Crete
Theravance Biopharma Investigational Site, Heraklion, Crete, 71110, Greece
Peloponnese
Theravance Biopharma Investigational Site, Patra, Peloponnese, 265 04, Greece
Fejér
Theravance Biopharma Investigational Site, Székesfehérvár, Fejér, 8000, Hungary
Hajdú-Bihar
Theravance Biopharma Investigational Site, Debrecen, Hajdú-Bihar, 4032, Hungary
Tolna County
Theravance Biopharma Investigational Site, Szekszárd, Tolna County, 7100, Hungary
Theravance Biopharma Investigational Site, Budapest, 1088, Hungary
Theravance Biopharma Investigational Site, Budapest, 1136, Hungary
Milano
Theravance Biopharma Investigational Site, Rozzano, Milano, 20089, Italy
Theravance Biopharma Investigational Site, Catanzaro, 88100, Italy
Theravance Biopharma Investigational Site, Pavia, 27100, Italy
Aichi-ken
Theravance Biopharma Investigational Site, Nagoya, Aichi-ken, 457-8511, Japan
Chiba
Theravance Biopharma Investigational Site, Abiko, Chiba, 270-1168, Japan
Theravance Biopharma Investigational Site, Sakura, Chiba, 285-8741, Japan
Fukuoka
Theravance Biopharma Investigational Site, Kurume, Fukuoka, 839-0809, Japan
Gifu
Theravance Biopharma Investigational Site, Ōgaki, Gifu, 503-8502, Japan
Gunma
Theravance Biopharma Investigational Site, Isesaki, Gunma, 372-0817, Japan
Hiroshima
Theravance Biopharma Investigational Site, Fukuyama-Shi, Hiroshima, 720-8520, Japan
Theravance Biopharma Investigational Site, Hatsukaichi, Hiroshima, 738-8503, Japan
Kanagawa
Theravance Biopharma Investigational Site, Kawasaki, Kanagawa, 211-8533, Japan
Miyagi
Theravance Biopharma Investigational Site, Sendai, Miyagi, 981-3213, Japan
Nagano
Theravance Biopharma Investigational Site, Suwa, Nagano, 392-8510, Japan
Oita Prefecture
Theravance Biopharma Investigational Site, Ōita, Oita Prefecture, 870-0033, Japan
Osaka
Theravance Biopharma Investigational Site, Fujiidera, Osaka, 583-0027, Japan
Theravance Biopharma Investigational Site, Izumiōtsu, Osaka, 595-0027, Japan
Saitama
Theravance Biopharma Investigational Site, Ageo, Saitama, 362-0075, Japan
Theravance Biopharma Investigational Site, Tokorozawa, Saitama, 359-1114, Japan
Toyama
Theravance Biopharma Investigational Site, Kurobe-shi, Toyama, 938-8502, Japan
Theravance Biopharma Investigational Site, Chiba, 260-0852, Japan
Theravance Biopharma Investigational Site, Fukuoka, 814-0180, Japan
Theravance Biopharma Investigational Site, Kumamoto, 860-0004, Japan
Theravance Biopharma Investigational Site, Tokyo, 135-8577, Japan
Theravance Biopharma Investigational Site, Tokyo, 136-0075, Japan
Theravance Biopharma Investigational Site, Tokyo, 152-8902, Japan
Greater Poland Voivodeship
Theravance Biopharma Investigational Site, Poznan, Greater Poland Voivodeship, 60-369, Poland
Theravance Biopharma Investigational Site, Poznan, Greater Poland Voivodeship, 61-113, Poland
Kuyavian-Pomeranian Voivodeship
Theravance Biopharma Investigational Site, Torun, Kuyavian-Pomeranian Voivodeship, 87-100, Poland
Theravance Biopharma Investigational Site, Włocławek, Kuyavian-Pomeranian Voivodeship, 87-800, Poland
Lesser Poland Voivodeship
Theravance Biopharma Investigational Site, Krakow, Lesser Poland Voivodeship, 31-501, Poland
Lodzki
Theravance Biopharma Investigational Site, Lodz, Lodzki, 90-302, Poland
Lower Silesian Voivodeship
Theravance Biopharma Investigational Site, Wroclaw, Lower Silesian Voivodeship, 53-333, Poland
Theravance Biopharma Investigational Site, Wroclaw, Lower Silesian Voivodeship, 54-416, Poland
Masovian Voivodeship
Theravance Biopharma Investigational Site, Piaseczno, Masovian Voivodeship, 05-500, Poland
Theravance Biopharma Investigational Site, Warsaw, Masovian Voivodeship, 00-635, Poland
Theravance Biopharma Investigational Site, Warsaw, Masovian Voivodeship, 00-728, Poland
Theravance Biopharma Investigational Site, Warsaw, Masovian Voivodeship, 02-653, Poland
Theravance Biopharma Investigational Site, Warsaw, Masovian Voivodeship, 03-580, Poland
Pomeranian Voivodeship
Theravance Biopharma Investigational Site, Sopot, Pomeranian Voivodeship, 81-756, Poland
Silesian Voivodeship
Theravance Biopharma Investigational Site, Tychy, Silesian Voivodeship, 43-100, Poland
West Pomeranian Voivodeship
Theravance Biopharma Investigational Site, Szczecin, West Pomeranian Voivodeship, 71-434, Poland
Theravance Biopharma Investigational Site, Szczecin, 71-685, Poland
Łódź Voivodeship
Theravance Biopharma Investigational Site, Ksawerów, Łódź Voivodeship, 95-054, Poland
Theravance Biopharma Investigational Site, Lodz, Łódź Voivodeship, 91-034, Poland
Świętokrzyskie Voivodeship
Theravance Biopharma Investigational Site, Staszów, Świętokrzyskie Voivodeship, 28-200, Poland
Theravance Biopharma Investigational Site, Coimbra, 3000-075, Portugal
Theravance Biopharma Investigational Site, Guimarães, 4835-044, Portugal
Theravance Biopharma Investigational Site, Leiria, 2410-197, Portugal
Theravance Biopharma Investigational Site, Lisbon, 1349-019, Portugal
Theravance Biopharma Investigational Site, Santa Maria da Feira, 4520-211, Portugal
Theravance Biopharma Investigational Site, Senhora da Hora, 4454-513, Portugal
Theravance Biopharma Investigational Site, Viana do Castelo, 4901-858, Portugal
Theravance Biopharma Investigational Site, Vila Nova de Gaia, 4434502, Portugal
Timiș County
Theravance Biopharma Investigational Site, Timișoara, Timiș County, 300002, Romania
Theravance Biopharma Investigational Site, Bucharest, 020125, Romania
Theravance Biopharma Investigational Site, Belgrade, 11000, Serbia
Theravance Biopharma Investigational Site, Belgrade, 11080, Serbia
Theravance Biopharma Investigational Site, Kragujevac, 34000, Serbia
Theravance Biopharma Investigational Site, Niš, 18000, Serbia
Theravance Biopharma Investigational Site, Subotica, 24000, Serbia
Theravance Biopharma Investigational Site, Zrenjanin, 23000, Serbia
Prešovsky
Theravance Biopharma Investigational Site, Prešov, Prešovsky, 080 01, Slovakia
Theravance Biopharma Investigational Site, Nitra, 949 01, Slovakia
Theravance Biopharma Investigational Site, Šahy, 936 01, Slovakia
Gauteng
Theravance Biopharma Investigational Site, Johannesburg, Gauteng, 2196, South Africa
Gangwon-do
Theravance Biopharma Investigational Site, Wŏnju, Gangwon-do, 26426, South Korea
Gyeonggi-do
Theravance Biopharma Investigational Site, Suwon, Gyeonggi-do, 16247, South Korea
Theravance Biopharma Investigational Site, Daegu, 42415, South Korea
Theravance Biopharma Investigational Site, Seoul, 03722, South Korea
Theravance Biopharma Investigational Site, Seoul, 06351, South Korea
Theravance Biopharma Investigational Site, Seoul, 130-702, South Korea
Theravance Biopharma Investigational Site, Seoul, 5505, South Korea
Theravance Biopharma Investigational Site, Barcelona, 08022, Spain
Theravance Biopharma Investigational Site, Madrid, 28006, Spain
Theravance Biopharma Investigational Site, Seville, 41013, Spain
Theravance Biopharma Investigational Site, Valencia, 46010, Spain
Theravance Biopharma Investigational Site, Kaohsiung City, 83301, Taiwan
Theravance Biopharma Investigational Site, Taichung, 40210, Taiwan
Theravance Biopharma Investigational Site, Tainan, 71004, Taiwan
Theravance Biopharma Investigational Site, Taipei, 116, Taiwan
KIEV CITY
Theravance Biopharma Investigational Site, Kiev, KIEV CITY, 04107, Ukraine
Kyiv City
Theravance Biopharma Investigational Site, Kyiv, Kyiv City, 01030, Ukraine
Theravance Biopharma Investigational Site, Kyiv, Kyiv City, 4107, Ukraine
Poltava Oblast
Theravance Biopharma Investigational Site, Kremenchuk, Poltava Oblast, 39617, Ukraine
Transcarpathian
Theravance Biopharma Investigational Site, Uzhhorod, Transcarpathian, 88000, Ukraine
Vinnytsya
Theravance Biopharma Investigational Site, Vinnytsia, Vinnytsya, 21005, Ukraine
Theravance Biopharma Investigational Site, Vinnytsia, Vinnytsya, 21029, Ukraine
Theravance Biopharma Investigational Site, Chernivtsi, 58001, Ukraine
Theravance Biopharma Investigational Site, Kharkiv, 61037, Ukraine
Theravance Biopharma Investigational Site #2, Lviv, 79010, Ukraine
Theravance Biopharma Investigational Site, Lviv, 79010, Ukraine
Theravance Biopharma Investigational Site, Ternopil, 46001, Ukraine
Theravance Biopharma Investigational Site, Uzhhorod, 88009, Ukraine
Theravance Biopharma Investigational Site, Vinnytsia, 20129, Ukraine
Theravance Biopharma Investigational Site, Vinnytsia, 21018, Ukraine
Theravance Biopharma Investigational Site, Zaporizhzhya, 69096, Ukraine
Theravance Biopharma Investigational Site, Zaporizhzhya, 69600, Ukraine